MetaVia, Inc. (MTVA)
1.29
+0.06
(+4.88%)
USD |
NASDAQ |
Oct 20, 16:00
1.27
-0.02
(-1.55%)
After-Hours: 06:35
MetaVia Net Income (Quarterly) : -5.316M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -5.316M |
| March 31, 2026 | -3.823M |
| December 31, 2025 | -1.93M |
| September 30, 2025 | -3.377M |
| June 30, 2025 | -3.995M |
| March 31, 2025 | -3.671M |
| December 31, 2024 | -5.173M |
| September 30, 2024 | -5.652M |
| June 30, 2024 | -10.05M |
| March 31, 2024 | -6.714M |
| December 31, 2023 | -5.314M |
| September 30, 2023 | -3.818M |
| June 30, 2023 | -0.734M |
| March 31, 2023 | -2.604M |
| December 31, 2022 | -4.676M |
| September 30, 2022 | -3.113M |
| June 30, 2022 | -3.303M |
| March 31, 2022 | -2.875M |
| December 31, 2021 | -4.578M |
| September 30, 2021 | -3.461M |
| June 30, 2021 | -3.921M |
| March 31, 2021 | -3.324M |
| Date | Value |
|---|---|
| December 31, 2020 | -19.51M |
| September 30, 2020 | -3.054M |
| June 30, 2020 | -2.384M |
| March 31, 2020 | -4.73M |
| December 31, 2019 | -11.16M |
| September 30, 2019 | -3.621M |
| June 30, 2019 | -1.901M |
| March 31, 2019 | -2.464M |
| December 31, 2018 | -3.656M |
| September 30, 2018 | -6.079M |
| June 30, 2018 | -6.678M |
| March 31, 2018 | -7.224M |
| December 31, 2017 | -6.746M |
| September 30, 2017 | -8.671M |
| June 30, 2017 | -10.50M |
| March 31, 2017 | -7.496M |
| December 31, 2016 | -7.214M |
| September 30, 2016 | -3.878M |
| June 30, 2016 | -1.391M |
| March 31, 2016 | -2.103M |
| March 31, 2015 | -2.279M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 5.316M |
| EPS Diluted (Quarterly) | -0.8962 |
| Enterprise Value | -3.974M |
| Earnings Yield | -313.2% |
| Normalized Earnings Yield | -313.91 |